What EUDAMED expects before your investigation starts

Written by HATEM RABEH, MD, MSc Ing

Your Clinical Evaluation Expert And Partner

in
S

The clinical investigation registry in EUDAMED is fundamentally different from what many experienced with older systems. It is not just about announcing that your study exists. It is about demonstrating upfront that your investigation complies with MDR requirements, that your protocol reflects the risk profile of your device, and that every party involved has done their part.

Many manufacturers misunderstand the timing. They finalize the protocol, get ethics approval, and only then approach the registry. That creates a mismatch. The registry expects alignment from the beginning, not reconciliation after the fact.

What EUDAMED Actually Registers

The clinical investigation module in EUDAMED is designed to capture structured information about your study before it starts enrolling subjects. This is not a voluntary publication. Under MDR Article 73, sponsors must submit specific data elements to ensure transparency and traceability.

The registry captures:

• Device identification linked to your UDI-DI
• Study design and primary objectives
• Risk classification and justification for investigation
• Ethics committee decisions per Member State
• Expected enrollment numbers and timelines
• Principal investigator and sponsor details

Each of these elements must match what your ethics committee reviewed and what your Notified Body sees in your clinical evaluation plan. Inconsistencies trigger questions. And those questions delay your study start.

The Timing Problem

Most manufacturers think the sequence goes like this: finalize protocol, submit to ethics, get approval, register in EUDAMED, then start enrollment. That linear view causes problems.

Here is what actually happens. EUDAMED expects registry submission before you start enrollment, but it also expects that what you register is already locked. If you register a protocol version that later changes based on ethics feedback, you must update the registry. Those updates are tracked. They are visible. And they raise questions about why your protocol was not stable before submission.

The better approach is to prepare your registry entry in parallel with your ethics submission. You do not wait until approval. You prepare the content based on your final protocol draft, so that the moment ethics approves, you can register without modification.

This parallel preparation forces you to think through what EUDAMED will ask before ethics even reviews your file. It surfaces misalignments early. And it ensures that your registry entry reflects exactly what was approved, not an approximation.

What happens if you register late?

If you enroll subjects before registering, you violate MDR Article 73. That is a serious compliance gap. Notified Bodies check registration status. If your study was active before the registry entry was complete, they will document that finding.

But even if you register before first enrollment, registering late means you have less time to correct errors. EUDAMED does not allow instant edits. If you submit incomplete data or discover a mismatch after submission, you must go through a correction process. That takes time. And during that time, your study status may show as incomplete or pending, which affects how Notified Bodies and regulators view your compliance posture.

What Each Field Actually Means

Let me walk through the fields that cause the most confusion, because manufacturers often misinterpret what EUDAMED is asking for.

Device identification and UDI-DI linkage

EUDAMED expects you to link your clinical investigation to the specific device version being studied. This is not about a general product family. It is about the exact configuration, software version, and intended use that your protocol describes.

If your device has multiple configurations, you must specify which one is under investigation. If you are testing a software update, the UDI-DI must reflect that version. Generic references do not work.

Why does this matter? Because EUDAMED cross-references your investigation registry with your device registration. If the UDI-DI in your investigation entry does not match what is registered in the device module, the system flags it. Notified Bodies see that flag. They will ask you to explain.

Study design and objectives

EUDAMED asks for your study design in structured fields. You cannot just paste your protocol synopsis. You must translate your design into predefined categories: randomized or non-randomized, controlled or single-arm, blinded or open-label.

The problem comes when your protocol describes a complex design that does not fit neatly into those categories. For example, if you are running a sequential design with adaptive sample size, how do you represent that in a fixed dropdown menu?

The answer is not to oversimplify. You select the closest match, but then you must ensure that your protocol synopsis in the free text field clarifies the actual design. This way, anyone reviewing your registry entry understands what you are really doing, not just what the dropdown suggests.

Ethics committee decisions

This is where timing becomes critical. EUDAMED expects you to register the ethics committee decision for each Member State where you plan to conduct the investigation. You cannot register a study as active without documenting ethics approval.

But here is the nuance. You can submit your registry entry before ethics approval, as long as you mark the study status correctly. The system allows you to indicate that ethics review is pending. Once approval comes through, you update the entry with the decision date and reference number.

The mistake manufacturers make is registering the study as approved when ethics approval is still conditional or pending additional information. That creates a false record. If a Notified Body or regulator checks the ethics committee directly and finds that approval was conditional, your registry entry becomes unreliable.

Always wait for unconditional approval before marking the study as approved in EUDAMED. If you are under time pressure, register the study as pending and update it once you have final approval. That is transparent. That is compliant.

The Public Visibility Factor

One aspect that manufacturers underestimate is that EUDAMED clinical investigation data is publicly accessible. Not every field, but key information about your study becomes visible once the registry entry is validated.

This means that your competitors, patients, and advocacy groups can see what you are investigating. They can see your study objectives, your device classification, and your enrollment numbers. They can track whether your study is ongoing, completed, or terminated early.

That public visibility changes how you write your registry entries. You cannot be vague. You cannot use internal jargon. Every field must be clear enough that an external reader can understand what you are doing and why.

But you also cannot be overly promotional. EUDAMED is not a marketing platform. If your study objectives read like a product brochure, it undermines credibility. Write for transparency, not persuasion.

What happens if you terminate a study early?

If you stop a study before planned completion, you must update the registry with the termination reason. That update is visible. Regulators see it. Notified Bodies see it. And it becomes part of your device history.

Early termination is not inherently problematic, but how you document it matters. If you terminate for safety reasons, you must explain what happened and how you addressed it. If you terminate for futility, you must clarify whether that reflects device performance or study design issues.

The registry does not allow you to hide negative outcomes. That is intentional. Transparency is a core principle of MDR. If your study did not go as planned, document it clearly and show what you learned. That demonstrates maturity, not failure.

How Notified Bodies Use the Registry

Notified Bodies do not just check that your study is registered. They use the registry to verify consistency across your technical documentation.

When they review your clinical evaluation report, they cross-reference the clinical investigation data you cited with what is registered in EUDAMED. If your CER describes a study with 150 subjects but the registry shows 100, they will ask why. If your CER claims the study is complete but the registry shows it is still ongoing, that is a deficiency.

The registry becomes a reference point for audits. It is not isolated from the rest of your documentation. Everything must align.

This is why I emphasize preparing your registry entry early. If you wait until the last moment, you do not have time to check for consistency. You rush through the fields, submit, and only later realize that your numbers do not match what you put in your CER or your PMCF plan.

What about multi-site studies?

If your investigation runs across multiple sites in different Member States, each site must be documented separately in EUDAMED. You cannot register a multi-country study with a single generic entry.

Each Member State has its own ethics committee approval. Each site has its own principal investigator. Each must be listed individually in the registry with the corresponding ethics decision.

This increases the administrative burden, but it also increases the risk of inconsistency. If one site starts enrollment before its ethics approval is registered, that creates a compliance gap even if the other sites are compliant.

The solution is to track each site separately from the beginning. Do not assume that one ethics approval covers multiple countries. Verify the requirements per Member State. Register each approval individually. And update the registry as each site progresses through the study lifecycle.

Practical Steps Before You Submit

Before you submit your registry entry, go through this checklist. It will save you from the most common mistakes.

Verify UDI-DI alignment. Check that the UDI-DI you reference in the investigation registry matches what is registered in the device module. If they do not align, resolve that discrepancy before submitting.

Confirm ethics committee details. Make sure you have the exact ethics committee name, decision date, and reference number as stated in the approval letter. Do not paraphrase. Use the exact wording.

Cross-check enrollment numbers. If your protocol says 150 subjects, the registry should say 150 subjects. If you later amend the protocol to increase enrollment, update the registry immediately after ethics approves the amendment.

Review your study design fields. Do not rush through the dropdowns. Each selection must accurately reflect your protocol. If you are uncertain which option fits best, document your reasoning internally so you can explain it if asked.

Write clear free text summaries. The synopsis and objectives fields are not optional. Use them to clarify anything that the structured fields cannot capture. Write as if a Notified Body auditor will read it, because they will.

What Comes After Registration

Once your study is registered and enrollment starts, the registry does not disappear. You must update it throughout the study lifecycle.

When you complete enrollment, update the registry. When you finish follow-up, update the registry. When you submit your final report to ethics, update the registry. Each milestone must be reflected.

These updates are tracked. Regulators can see how long it took you to move from one phase to the next. If your study shows as ongoing for years without updates, that raises questions about whether the study is actually progressing or whether you forgot to maintain the registry.

In my experience, manufacturers often register studies properly at the start, then neglect updates until a Notified Body audit reminds them. By then, the registry is months out of date, and they must retrospectively reconstruct the timeline.

Do not let that happen. Assign someone internally to maintain the registry as part of the study closeout process. Make it a checklist item. That way, your registry always reflects the current state of your investigation.

The clinical investigation registry in EUDAMED is not a bureaucratic hurdle. It is a transparency mechanism that holds manufacturers accountable for the claims they make about their devices. If you approach it as a formality, it will become a source of deficiencies. If you approach it as an integrated part of your clinical evaluation strategy, it reinforces the quality and credibility of your entire submission.

What you register in EUDAMED becomes part of your device history. Make sure it tells the right story.

Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.